(19)
(11) EP 4 573 370 A1

(12)

(43) Date of publication:
25.06.2025 Bulletin 2025/26

(21) Application number: 23853755.9

(22) Date of filing: 16.08.2023
(51) International Patent Classification (IPC): 
G01N 33/68(2006.01)
C07H 21/02(2006.01)
 A61K 38/00(2006.01)
C12N 15/113(2010.01)
(52) Cooperative Patent Classification (CPC):
G01N 33/56983; G01N 2333/165; G01N 33/6896; G01N 2333/4716; G01N 2800/52; C12N 2310/16; C12N 2310/11; C12N 15/1136; C12N 2310/315; C12N 2310/341; C12N 2310/3341
 
C-Sets:
C12N 2310/321, C12N 2310/3525;
(86) International application number:
PCT/AU2023/050777
(87) International publication number:
WO 2024/036373 (22.02.2024 Gazette 2024/08)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 16.08.2022 US 202263398363 P
16.02.2023 AU 2023900376

(71) Applicant: Percheron Therapeutics Ltd
Toorak, Victoria 3142 (AU)

(72) Inventor:
  • TACHAS, George
    Toorak, Victoria 3142 (AU)

(74) Representative: Studio Torta S.p.A. 
Via Viotti, 9
10121 Torino
10121 Torino (IT)

   


(54) BIOMARKERS AND USES THEREOF IN DIAGNOSIS AND TREATMENT OF NEUROLOGICAL POST ACUTE SEQUELAE OF COVID 19 (NPASC)